Shanghai AbelZeta Ltd.

Quick facts

Phase 2 pipeline

• Mesenchymal progenitor cells
• No mesenchymal progenitor cells
• ReJoinTM

Phase 1 pipeline

• autologous immune cell therapy
• Autologous T cells-Based Immunotherapy
• C-CAR-011
• C-CAR011
• C-CAR031
• Mesenchymal stem cells high-dose group
• Mesenchymal stem cells low-dose group
• Mesenchymal stem cells mid-dose group

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Shanghai AbelZeta Ltd. portfolio CI brief
• Shanghai AbelZeta Ltd. pipeline updates RSS